This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1203 entries already.
The new fund supports of NaturalX, which has its first closing at €100m, supports proactive healthcare, filling a market gap as consumers take control of their own health journey.
German BRAIN Biotech AG and the Switzerland’s PX Group will extend its partnership within the framework of the PX Urban Mining Initiative. The extension builds on previous work, which focused on providing a proof of concept for the biological recovery of gold from e-waste and other gold-containing side streams.
German API and antibody drug conjugate (ADC) CDMO Axplora Group GmbH has announced an investment of €50m in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases.
Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI) has granted US$5m to RNA formulation specialis Ethris to support studies that demonstrate spray-dried RNA vaccines remain stable at room temperature and are suitable for mucosal delivery.
Now that US President Donald Trump has loudly announced his intention to withdraw from the Paris climate targets and refocus the US economy on fossil fuel production, Europe, which is still a leader in the bioeconomy, is sensing an opportunity. A new cluster alliance of 14 production sites wants to advance the high-tech bioeconomy.
Hair loss therapeutics developer Mallia Therapeutics and Northway Biotech have partners to set up a manufacturing process of soluble CD83 protein to prevent and cure hair loss.
Helsinki-based Aplagon has secured €7m in financing to advance its therapeutic APAC into Phase 2a clinical trials.
One day after presenting its competition strategy, the EU Commission has launched an EU Biotech and Biomanufacturing Hub. The collection of information is intended to help biotech start-ups navigate through the jungle of EU funding measures and provide access to networks that help with patenting, product authorisation and compliance with EU regulations.
Dutch venture capital firm Forbion revealed that its BioEconomy Fund I has amassed €164.5m. This surpasses the fund’s initial target of €150m, highlighting the increasing interest from investors in the commercial viability of biotech solutions that tackle worldwide sustainability issues.
The FDA has approved Novo Nordisk’s blockbuster drug Ozempic (semaglutide) for patients with chronic kidney disease who also have type 2 diabetes.